CR20150294A - Inhibidores de bmi-1 de pirimidina inversa sustituida - Google Patents

Inhibidores de bmi-1 de pirimidina inversa sustituida

Info

Publication number
CR20150294A
CR20150294A CR20150294A CR20150294A CR20150294A CR 20150294 A CR20150294 A CR 20150294A CR 20150294 A CR20150294 A CR 20150294A CR 20150294 A CR20150294 A CR 20150294A CR 20150294 A CR20150294 A CR 20150294A
Authority
CR
Costa Rica
Prior art keywords
bmi
replaced
inhibitors
pyrimidine
level
Prior art date
Application number
CR20150294A
Other languages
English (en)
Inventor
Wu Du
Nadiya Sydorenko
Ramil Baiazitov
Hongyu Ren
Thomas W Davis
Steven D Paget
Young-Choon Moon
Liangxian Cao
Chang-Sun Lee
Ronggang Liu
Richard Gerald Wilde
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CR20150294A publication Critical patent/CR20150294A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

Compuestos inversos de pirimidina sustituidos con amina y formas de la misma que inhiben la función y reducen el nivel de la proteína del sitio de integración 1 (Bmi-1) del virus de la leucemia de Moloney específico de células B para su uso para inhibir la función de Bmi-1 y reducir el nivel de Bmi-1 para el tratamiento de un cáncer mediado por Bmi-1 se describen en el presente documento
CR20150294A 2012-11-21 2015-06-05 Inhibidores de bmi-1 de pirimidina inversa sustituida CR20150294A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Publications (1)

Publication Number Publication Date
CR20150294A true CR20150294A (es) 2015-08-20

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150294A CR20150294A (es) 2012-11-21 2015-06-05 Inhibidores de bmi-1 de pirimidina inversa sustituida

Country Status (32)

Country Link
US (3) US10428050B2 (es)
EP (1) EP2922828B1 (es)
JP (3) JP6412503B2 (es)
KR (4) KR102356487B1 (es)
CN (2) CN104918919A (es)
AR (1) AR093579A1 (es)
AU (1) AU2013348009C1 (es)
BR (1) BR112015011760B1 (es)
CA (1) CA2892045C (es)
CL (1) CL2015001377A1 (es)
CR (1) CR20150294A (es)
CU (1) CU24387B1 (es)
DK (1) DK2922828T3 (es)
EA (2) EA031405B1 (es)
EC (1) ECSP15019948A (es)
ES (1) ES2821529T3 (es)
HK (1) HK1215032A1 (es)
IL (2) IL238871B (es)
MA (1) MA38208B1 (es)
MX (2) MX2015006469A (es)
NI (1) NI201500072A (es)
NZ (2) NZ746607A (es)
PE (1) PE20151413A1 (es)
PH (1) PH12015501130A1 (es)
PL (1) PL2922828T3 (es)
PT (1) PT2922828T (es)
SA (1) SA517381847B1 (es)
SG (2) SG10201600149VA (es)
TW (1) TWI623531B (es)
UA (1) UA118094C2 (es)
WO (1) WO2014081906A2 (es)
ZA (1) ZA201503642B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151413A1 (es) 2012-11-21 2015-10-23 Ptc Therapeutics Inc Inhibidores de bmi-1 de pirimidina inversa sustituida
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6524094B2 (ja) 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3402780A1 (en) * 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
EP3580700A4 (en) 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
MX2021008523A (es) * 2019-01-15 2021-11-12 Ptc Therapeutics Inc Metodo para tratar una leucemia mieloide aguda.
WO2020176610A1 (en) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
EP3938368B1 (en) 2019-03-11 2023-06-07 PTC Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof
CA3134521A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
MX2021011688A (es) * 2019-03-27 2022-01-24 Ptc Therapeutics Inc Combinaciones utiles en un metodo para tratar sarcoma.
WO2020200209A1 (zh) * 2019-04-02 2020-10-08 成都海创药业有限公司 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) * 1973-09-20 1977-11-30 Delalande Sa
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
IN188411B (es) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
ATE415396T1 (de) 2000-09-20 2008-12-15 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
MXPA03007266A (es) 2001-02-20 2003-12-04 Astrazeneca Ab 2-arilamino-pirimidinas para tratamiento de desordenes relacionados a glucogeno-sintasa cinasa-3(gsk3).
EP1975620A3 (en) * 2001-03-02 2008-12-24 GPC Biotech AG Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
WO2003004492A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) * 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
DE60331187D1 (de) 2002-05-23 2010-03-25 Cytopia Res Pty Ltd Kinaseinhibitoren
WO2004002963A1 (ja) 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7582630B2 (en) 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
UY29414A1 (es) 2005-03-10 2006-10-02 Bayer Pharmaceuticals Corp Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
BRPI0717773A2 (pt) 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
MX2009006536A (es) 2006-12-22 2009-06-26 Novartis Ag Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
TW200846344A (en) 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2331527A1 (en) * 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
EP2397479A4 (en) 2009-02-12 2012-08-01 Astellas Pharma Inc HETERO RING DERIVATIVE
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010138575A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
HUE031048T2 (en) * 2009-06-17 2017-06-28 Vertex Pharma Influenza virus replication inhibitors
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
NZ601143A (en) 2010-01-12 2014-10-31 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2606126B1 (en) * 2010-08-19 2016-05-18 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
HUE027256T2 (en) 2010-09-13 2016-08-29 Novartis Ag Triazine-oxadiazoles
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
EP2796456A1 (en) 2010-12-09 2014-10-29 Amgen Inc. Bicyclic compounds as Pim inhibitors
US9850227B2 (en) 2011-02-25 2017-12-26 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
PE20151413A1 (es) 2012-11-21 2015-10-23 Ptc Therapeutics Inc Inhibidores de bmi-1 de pirimidina inversa sustituida
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
ZA201503642B (en) 2020-10-28
WO2014081906A3 (en) 2014-07-17
CA2892045C (en) 2022-05-31
CL2015001377A1 (es) 2016-02-19
TWI623531B (zh) 2018-05-11
JP2019031509A (ja) 2019-02-28
PE20151413A1 (es) 2015-10-23
JP2016504290A (ja) 2016-02-12
KR102455889B1 (ko) 2022-10-17
AU2013348009C1 (en) 2019-08-08
EP2922828A2 (en) 2015-09-30
US10428050B2 (en) 2019-10-01
PH12015501130A1 (en) 2015-08-03
MA38208B1 (fr) 2021-12-31
MX2015006469A (es) 2015-10-29
KR20220143164A (ko) 2022-10-24
ES2821529T3 (es) 2021-04-26
BR112015011760A2 (pt) 2017-07-11
AU2013348009A1 (en) 2015-06-04
US20150315182A1 (en) 2015-11-05
EA031405B1 (ru) 2018-12-28
ECSP15019948A (es) 2016-01-29
IL238871B (en) 2019-03-31
SG11201503982XA (en) 2015-06-29
JP6412503B2 (ja) 2018-10-24
EA201890142A1 (ru) 2018-06-29
NZ708909A (en) 2019-11-29
HK1215032A1 (zh) 2016-08-12
NI201500072A (es) 2016-01-18
WO2014081906A2 (en) 2014-05-30
AU2013348009B2 (en) 2018-05-17
EA201590992A1 (ru) 2015-11-30
KR102356487B1 (ko) 2022-02-08
KR20150086345A (ko) 2015-07-27
KR102275676B1 (ko) 2021-07-12
NZ746607A (en) 2019-11-29
KR20220016305A (ko) 2022-02-08
CU20150053A7 (es) 2015-11-27
EA035349B1 (ru) 2020-05-29
AR093579A1 (es) 2015-06-10
BR112015011760B1 (pt) 2022-12-06
CN104918919A (zh) 2015-09-16
TW201427972A (zh) 2014-07-16
MX2021009892A (es) 2021-09-14
US20220064150A1 (en) 2022-03-03
EP2922828A4 (en) 2016-07-27
CN111423417B (zh) 2022-11-15
IL265253A (en) 2019-05-30
US11180483B2 (en) 2021-11-23
EP2922828B1 (en) 2020-07-08
US20200024260A1 (en) 2020-01-23
IL238871A0 (en) 2015-07-30
UA118094C2 (uk) 2018-11-26
CN111423417A (zh) 2020-07-17
SA517381847B1 (ar) 2021-07-17
PL2922828T3 (pl) 2020-12-28
KR20210088740A (ko) 2021-07-14
SG10201600149VA (en) 2016-02-26
JP6918898B2 (ja) 2021-08-11
PT2922828T (pt) 2020-10-12
JP2020055815A (ja) 2020-04-09
CA2892045A1 (en) 2014-05-30
JP6617186B2 (ja) 2019-12-11
DK2922828T3 (da) 2020-08-31
CU24387B1 (es) 2019-03-04

Similar Documents

Publication Publication Date Title
CR20150294A (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CL2022001671A1 (es) Inhibidores de sos1
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CR20180367A (es) Compuestos útiles como inhibidores de cinasa
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
CO2017006920A2 (es) Picolinamidas como fungicidas
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
BR112016025427A2 (pt) processos de preparação de um inibidor de jak1 e formas do mesmo
CL2015002932A1 (es) Inhibidores de proteína quinasa
SV2016005149A (es) Polimorfo de los inhibidores de la syk
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016002642A (es) Inhibidores de la bmi-1 de pirimidina sustituida.
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CO2019006220A2 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CO2019008110A2 (es) Activador de nrf2
CL2018000941A1 (es) Regulación del uso de nitrógeno